They then observed that serelaxin treatment in vivo reduced isoproterenol-induced cardiomyopathy along with interstitial TGF-β1 levels and NLPR-3 inflammasome activity in the ventricle [113]. The gene discussed is TGFB1; the disease is cardiomyopathy.